Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

Tiziana Life Sciences (NASDAQ: TLSA) said CEO Ivor Elrifi will present at the 9th Annual Neuroscience Innovation Forum on Jan 11, 2026 at 2:00 PM PT at the Marines' Memorial Club in San Francisco during J.P.

Rhea-AI Summary

Tiziana Life Sciences (NASDAQ: TLSA) said CEO Ivor Elrifi will present at the 9th Annual Neuroscience Innovation Forum on Jan 11, 2026 at 2:00 PM PT at the Marines' Memorial Club in San Francisco during J.P. Morgan Healthcare Conference Week. Senior management will attend and be available for one-on-one investor and partner meetings.

The presentation will highlight the company's lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody intended to modulate the immune system and reduce microglial activation in neurodegenerative and neuroinflammatory conditions, including non-active secondary progressive multiple sclerosis.

Argus Jan 9 session

-3.38% close to close Open Argus

Details

News Market Reaction – TLSA

On Jan 9, the day this news came out, TLSA closed 3.38% below the previous close.

Data tracked by StockTitan Argus for the Jan 9 session.

Market Context

This announcement highlights Tiziana’s participation in a high-profile neuroscience forum, reinforci...

Analysis

This announcement highlights Tiziana’s participation in a high-profile neuroscience forum, reinforcing its focus on intranasal foralumab for neurodegenerative and neuroinflammatory conditions, including non-active secondary progressive multiple sclerosis. In recent months, the company reported Phase 2 Alzheimer’s trial progress, ALS program inclusion in a major research framework, and insider share purchases. Investors may watch for incremental clinical detail from the presentation, follow-up partnering activity, and future readouts expected in 2026 to better gauge the program’s trajectory.

Key Figures

Forum edition: 9th Annual Presentation time: 2:00 PM PT Presentation date: January 11, 2026

Forum edition

9th Annual

Neuroscience Innovation Forum

Presentation time

2:00 PM PT

Scheduled on January 11, 2026

Presentation date

January 11, 2026

Corporate presentation in San Francisco

Historical Context

5 past events · Latest: Dec 29

5 events

1. Dec 29

   Safety update

   24h Move

   +4.7%

   FDA safety report showed 37.4 patient-years exposure with no serious events.

2. Dec 19

   Insider share purchase

   24h Move

   +5.6%

   Executive Chairman increased holdings to 43,374,830 shares, 36.08% of capital.

3. Dec 17

   Nasdaq bell ceremony

   24h Move

   -5.8%

   Closing bell event highlighting progress of intranasal foralumab pipeline.

4. Dec 17

   Phase 2 trial start

   24h Move

   -5.8%

   First patient dosed in Phase 2 Alzheimer’s trial of intranasal foralumab.

5. Dec 15

   CEO share purchase

   24h Move

   -10.7%

   CEO bought 163,400 shares in open market, raising total purchased holdings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

anti-cd3 monoclonal antibody, microglial activation, neurodegenerative, multiple sclerosis, +1 more

5 terms

anti-cd3 monoclonal antibody medical

"intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces"

A lab-made antibody engineered to attach to CD3, a protein found on T cells, so it can change how those immune cells behave. Investors care because these drugs can act like a targeted brake on an overactive immune system—useful for autoimmune disease, transplant rejection or as part of cancer therapies—but they also carry clinical trial, safety and regulatory risks that determine commercial success.

microglial activation medical

"designed to modulate the immune system and reduce microglial activation in"

Microglial activation is when the brain’s resident immune cells — microglia — switch from a resting, maintenance role into an alert, defensive state, similar to a neighborhood cleanup crew suddenly racing to douse a small fire. For investors, this matters because persistent or excessive activation is a hallmark of many neurological diseases, affects how drugs perform in trials, and can drive regulatory and market reactions to therapies aimed at calming or harnessing this response.

neurodegenerative medical

"reduce microglial activation in neurodegenerative conditions."

Neurodegenerative describes diseases where nerve cells in the brain or spinal cord progressively lose function and die, causing worsening movement, memory or other mental abilities over time. For investors this matters because such conditions create large, long-term needs for therapies and caregiving; developing treatments often requires lengthy, expensive research and regulatory testing but can lead to substantial, sustained market opportunities if a therapy proves effective — like fixing the wiring in a whole neighborhood rather than a single house.

multiple sclerosis medical

"diseases such as non-active secondary progressive multiple sclerosis and other"

A chronic neurological disease in which the immune system damages the protective coating (like insulation on electrical wires) around nerves, disrupting signals between the brain and body and causing symptoms such as numbness, weakness, vision problems, fatigue and mobility issues. It matters to investors because the unpredictability and long-term nature of the condition drive ongoing demand for treatments, influence the value of companies developing therapies, affect healthcare costs and shape regulatory and reimbursement decisions.

neuroinflammatory medical

"multiple sclerosis and other neuroinflammatory conditions."

Neuroinflammatory describes inflammation occurring in the brain, spinal cord or peripheral nerves when the body's immune response becomes active in nervous tissue. For investors, it matters because neuroinflammatory processes are central to many neurological diseases and can drive demand for new drugs, affect clinical trial outcomes, and influence regulatory decisions—similar to how a neighborhood dispute can change local services and property values, inflammation can reshape treatment needs and company prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Chief Executive Officer Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum, organized by Sachs Associates. The presentation is scheduled for 2:00 PM PT on January 11, 2026, at the Marines' Memorial Club in San Francisco, California, during J.P. Morgan Healthcare Conference Week.

Members of Tiziana's senior management team will also attend the forum and be available for one-on-one meetings with investors, partners, and other stakeholders.

The 9th Annual Neuroscience Innovation Forum is a premier industry event featuring keynotes, panel discussions, and company presentations focused on advances in therapeutics, neurotechnology, and diagnostics for neurological disorders. Tiziana's presentation will highlight the Company's lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody designed to modulate the immune system and reduce microglial activation in neurodegenerative conditions.

“We are excited to participate in this prestigious forum alongside leading innovators in neuroscience,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “This event provides an important platform to share updates on our clinical progress with intranasal foralumab and to engage with potential partners as we advance therapies for patients suffering from devastating diseases such as non-active secondary progressive multiple sclerosis and other neuroinflammatory conditions.”

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biologic candidate that has been shown to stimulate T regulatory cells when dosed intranasally. Currently, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Tiziana Life Sciences (TLSA) presenting at the Neuroscience Innovation Forum?

Tiziana (TLSA) will present on January 11, 2026 at 2:00 PM PT at the Marines' Memorial Club in San Francisco.

What will Tiziana (TLSA) discuss about intranasal foralumab at the January 11 presentation?

The presentation will highlight clinical progress and the drug's mechanism as a fully human anti-CD3 monoclonal antibody aimed at modulating immunity and reducing microglial activation.

Can investors meet Tiziana management at the Neuroscience Innovation Forum during J.P. Morgan week?

Yes. Tiziana said senior management will attend the forum and be available for one-on-one meetings with investors and partners.

Which conditions will Tiziana reference for intranasal foralumab in the forum presentation?

The company plans to discuss development for neurodegenerative and neuroinflammatory conditions, including non-active secondary progressive multiple sclerosis.

Where and when is the 9th Annual Neuroscience Innovation Forum taking place during J.P. Morgan week?

The forum is held during J.P. Morgan Healthcare Conference Week in San Francisco; Tiziana's presentation is at the Marines' Memorial Club on Jan 11, 2026.